Comparison between rioprostil* * Bay o 6893, Bayer, Leverkusen, GFR. and sucralfate in the treatment of erosive duodenitis

M. Guslandi, S. Passaretti, E. Masci, P. A. Testoni, P. Salvini

Research output: Contribution to journalArticle

Abstract

Thirty outpatients of both sexes with endoscopic evidence of autonomous erosive duodenitis were randomly treated with either rioprostil* (a PGE1 derivative) 200 μg b.i.d or with sucralfate 1 g t.i.d for four weeks. Unhealed patients continued the ongoing treatment for a further 4-week period. Both drugs were found significantly effective in inducing relief of dyspeptic symptoms. At eight weeks complete disappearance of duodenal erosions was observed in 57.2% of patients on rioprostil and in 64.3% on sucralfate. No significant differences between the two drugs were found in either their clinical or endoscopic effectiveness. Neither diarrhoea nor other side-effects were reported with rioprostil, while nausea was experienced by two patients treated with sucralfate. Rioprostil proved to be a safe and effective therapeutic agent in gastroduodenal disorders where the use of cytoprotective drugs is required.

Original languageEnglish
Pages (from-to)167-171
Number of pages5
JournalClinical Trials Journal
Volume24
Issue number2
Publication statusPublished - 1987

Keywords

  • cytoprotection
  • Erosive duodenitis
  • rioprostil
  • sucralfate

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Comparison between rioprostil* * Bay o 6893, Bayer, Leverkusen, GFR. and sucralfate in the treatment of erosive duodenitis'. Together they form a unique fingerprint.

  • Cite this